Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Olmesartan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Olmesartan. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2004-002077-23 Sponsor Protocol Number: MeIn/03/Olm-Hyp/001 Start Date*: 2005-08-24
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
    Full Title: Efficacy and safety of Olmesartan medoxomil in elderly patients with mild to moderate hypertension
    Medical condition: Male or female outpatients, aged 65-89 years, with mild to moderate essential hypertension (sDBP>=90mmHg and sSBP>=140mmHg)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IE (Completed) AT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003005-41 Sponsor Protocol Number: CS0866-A-U101 Start Date*: 2015-07-24
    Sponsor Name:Sankyo Pharma Development
    Full Title: A Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of a Compounded 4 mg/mL Olmesartan Medoxomil Suspension (Total Dose 40 mg) and 40 mg Olmesartan Medoxomil Tablets (Beni...
    Medical condition: Not applicable - Healthy Volunteer study
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-003249-10 Sponsor Protocol Number: FNH-DS001 Start Date*: 2009-04-29
    Sponsor Name:University of the Saarland
    Full Title: Olmesartan, Oxidant Stress and in Vivo Re-Endothelialization Capacity of Endothelial Progenitor Cells from Patients with Chronic Kidney Disease (OECD Study)
    Medical condition: We will investigate the effect of Olmesartan Medoxomil 40 mg on the reendothelialization capacity of Endothelial Progenitor Cells in patients with chronic kidney disease. In this clinical setting O...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014349-10 Sponsor Protocol Number: OLMESARTAN2009 Start Date*: 2010-05-18
    Sponsor Name:Fundació institut d'investigació Biomèdica de Girona (IdibGi)
    Full Title: Reducción de la excreción urinaria de albumina y mejora de la rigidez vascular. Efectos del Olmesartan a dosis media y altas
    Medical condition: enfermos hipertensos
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003470-17 Sponsor Protocol Number: KKL172014 Start Date*: Information not available in EudraCT
    Sponsor Name:Krka, d.d. Novo mesto
    Full Title: The efficacy and safety of olmesartan medoxomil/amlodipine fixed combination in patients with grade 1 to grade 2 arterial hypertension. An international randomized, double-blind, 10-week multi-fact...
    Medical condition: Primary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-004249-42 Sponsor Protocol Number: Sevicontrol-2 Start Date*: 2011-12-09
    Sponsor Name:IPPMed GmbH
    Full Title: SEVICONTROL-2: Efficacy and Safety of a sequential therapy change from Candesartan 32 mg to the fixed combination of olmesartan 40 mg/amlodipine 10 mg in patients with poorly controlled moderate hy...
    Medical condition: moderate hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002534-18 Sponsor Protocol Number: CVAH631BDE10 Start Date*: 2004-11-24
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open, multicenter study to evaluate the efficacy and safety of a 4 week therapy with CoDiovan 160/25 (fixed dose combination of valsartan 160 mg plus HCTZ 25 mg) in patients not adequately respo...
    Medical condition: patients with hypertension
    Disease: Version SOC Term Classification Code Term Level
    M15 10020772 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000668-16 Sponsor Protocol Number: V1-19012014 Start Date*: 2014-05-06
    Sponsor Name:ATVB Verein
    Full Title: The LOW-BP-VIENNA (Lowering Blood Pressure in Primary Care in Vienna) Trial
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003534-25 Sponsor Protocol Number: CS8635-A-E302 Start Date*: 2009-05-13
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: A randomised, double-blind, parallel group study evaluating the efficacy and safety of co administration of triple combinations of olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide...
    Medical condition: Essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) NL (Completed) ES (Completed) BE (Completed) CZ (Completed) DK (Completed) BG (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005556-32 Sponsor Protocol Number: CS866CM-B-E303 Start Date*: 2007-07-30
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essentia...
    Medical condition: Essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003060-22 Sponsor Protocol Number: DSE-866-45 Start Date*: 2008-04-10
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: A 24-WEEK MULTICENTRE, RANDOMISED, DOUBLE BLIND, CONTROLLED, PARALLEL GROUP NON-INFERIORITY STUDY TO ASSESS THE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL VERSUS CANDESARTAN CILEXETIL IN PATIENTS ...
    Medical condition: Patients with symptomatic, clinically stable CHF with left ventricular systolic dysfunction [NYHA class II-IV and left ventricular ejection fraction (LVEF) < 40%] and elevated BNP levels (>400 pg/m...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Prematurely Ended) DE (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-003876-37 Sponsor Protocol Number: CS866CM-B-E301 Start Date*: 2006-11-28
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy
    Medical condition: Essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-018774-21 Sponsor Protocol Number: MeIn/08/OLMAML-Hyp/001 Start Date*: 2010-08-04
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA
    Full Title: Tratamiento con Olmesartán + Amlodipino en pacientes diabéticos: evaluación del control de la presión sanguínea 48 horas después de la última administración (dosis omitida)
    Medical condition: Hipertensión
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002899-14 Sponsor Protocol Number: CLCZ696A2216 Start Date*: 2012-11-22
    Sponsor Name:NOVARTIS FARMA
    Full Title: A randomized, double-blind, active-controlled, multicenter, 52-week study to evaluate the safety and efficacy of an LCZ696 regimen on arterial stiffness through assessment of central blood press...
    Medical condition: elderly Hypertensive patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000450-75 Sponsor Protocol Number: CS8663-A-E303 Start Date*: 2005-10-10
    Sponsor Name:Daiichi Sankyo Europe GmbH
    Full Title: Add-on Study of Olmesartan Medoxomil in Patients with Moderate to Severe Hypertension not Achieving Target Blood Pressure on Amlodipine 5 mg Alone
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    7.0 10015488 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005720-15 Sponsor Protocol Number: CLZC696A2224 Start Date*: 2013-09-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, active-controlled, parallel group, 52-week study to evaluate the effect of LCZ696 compared to olmesartan on regional aortic stiffness in subjects with essential hyperten...
    Medical condition: Hypertensive patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10047065 Vascular disorders SOC
    18.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004235-31 Sponsor Protocol Number: SEVICONTROL-1 Start Date*: 2011-12-09
    Sponsor Name:IPPMed GmbH
    Full Title: SEVICONTROL-1: Efficacy and safety of a fixed combination of olmesartan 40 mg/amlodipin 10 mg in patients with moderate essential hypertension not sufficiently controlled under monotherapy with can...
    Medical condition: moderate essential arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10015491 Essential hypertension, unspecified LLT
    14.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002191-98 Sponsor Protocol Number: PREVARENAL-08 Start Date*: 2008-11-27
    Sponsor Name:Servicio de Nefrologia-Hospital Universitario Vall d'Hebron
    Full Title: "Efecto del ARA-II Olmesartan sobre el metabolismo del potasio en pacientes con insuficiencia renal crónica"
    Medical condition: Microalbuminúria, hipertensión arterial y renoprotección en la insuficiencia renal crónica.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000571-25 Sponsor Protocol Number: HTA-OBESIDAD-2016 Start Date*: 2016-06-16
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: Seeking the ideal anti-hypertensive therapy in obesity-related hypertension. An open-label, single center, randomized clinical trial.
    Medical condition: obesity linked hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016693-33 Sponsor Protocol Number: CSPA100ADE01 Start Date*: 2010-05-11
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the single pill (SPC) combination of Aliskiren 300 mg / Amlodipine 10 mg in hypertensive patients not a...
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:12:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA